Scientist, Cell Therapy Process Development (In Vivo CAR-T)
Bristol Myers Squibb · Seattle, WA · 2 wk ago
On-siteAnalyst$123k–$149k/yrFull-time
About the role
The Cell Therapy Thematic Research Center is one of BMS’s differentiated research platforms delivering innovative therapies to patients. Our mission is to drive leadership in the use of cellular therapies to harness the power of the immune system in treating hematologic malignancies, solid cancers, and autoimmune disease. More specifically, our discovery and translational scientists are focused on developing next-generation, engineered cell-based therapies. The team is committed to discovering and developing transformative therapies that harness the power of the immune system to improve patient outcomes.
Responsibilities
- Design and execute laboratory experiments to evaluate gene delivery and cell engineering strategies for CAR-T manufacturing feasibility
- Lead workstreams and experiments focused on the optimization and implementation of scalable lentiviral vector production for in vivo CAR-T therapy platforms
- Document experimental workflows, results, and deviations in electronic laboratory notebooks to ensure reproducibility and process understanding
- Perform data analysis and communicate findings clearly to enable informed decision-making by research and development teams
- Participate in cross-functional project teams and effectively communicate CT-PRE activities, data, and recommendations
- Collaborate closely with team members to coordinate experimental execution and deliver study outcomes
- Train and mentor junior team members as appropriate
Requirements
- Experience with viral vector process development, including upstream production (e.g., suspension culture, transfection parameters, bioreactor scale-up) and downstream purification and concentration strategies
- Strong understanding of viral transduction mechanisms, tropism and integration
- Familiarity with analytical characterization and critical quality attributes for an in vivo CAR-T drug product (titer, purity, potency, sterility)
- Understanding of T-cell biology and immunology relevant to CAR-T – activation, transduction efficiency, phenotype and functional assays
- Experience with T-cell manufacturing workflows – apheresis material handling, activation, gene delivery, expansion, formulation
- Understanding of statistical design of experiments methodology and data analysis for process optimization
- Familiarity with lipid nanoparticle (LNP) or other nanoparticle-based delivery systems for in vivo and/or ex vivo T-cell targeting and engineering
- Knowledge of, or hands-on experience with, site-specific gene-editing (preferably CRISPR-Cas, base or prime editing) technologies
- Awareness of incorporation of cell-targeting ligands in vectors, for in vivo T-cell, or organ-selective targeting
- Effective written and verbal communication skills for exchanging technical and scientific information with cross-functional teams
Qualifications
- Bachelor’s Degree in the Life Sciences with 5+ years of academic and/or industry experience
- Master’s Degree in the Life Sciences with 3+ years of academic and/or industry experience
- Ph.D. or equivalent advanced degree in the Life Sciences
Skills
- Strong scientific rigor through critical thinking, problem-solving, troubleshooting, and attention to detail
Benefits
- Health Coverage: Medical, pharmacy, dental, and vision care
- Wellbeing Support: Programs such as BMS Well-Being Account, BMS Living Life Better, and Employee Assistance Programs (EAP)
- Financial Well-being and Protection: 401(k) plan, short- and long-term disability, life insurance, accident insurance, supplemental health insurance, business travel protection, personal liability protection, identity theft benefit, legal support, and survivor support
- Paid Time Off: Flexible time off (unlimited, with manager approval), 11 paid national holidays (not applicable to employees in Phoenix, AZ, Puerto Rico or Rayzebio employees), 160 hours annual paid vacation for new hires with manager approval, and an annual Global Shutdown between Christmas and New Years Day